The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278

Marco Treskes, Ulbe Holwerda, Leo G J Nijtmans, Herbert M. Pinedo, Wim J F van der Vijgh

Research output: Contribution to journalArticle

Abstract

The reversibility of cisplatin-protein interactions by the modulating agent WR2721, its active thiol-metabolite WR1065, and the symmetrical disulfide WR33278 was studied using the model compounds (Pt(diethylenetriammine) monofunctionally bound to the sulfur in glutathione (Pt(dien)SG) and Pt(diethylenetriammine) monofunctionally bound to the sulfur in S-methylglutathione (Pt(dien)SMeG). Both model compounds could be quantified by high-performance liquid chromatography (HPLC) with UV detection. The Pt-cysteine-like bond in Pt(dien)SG could not be reversed by any of the WR compounds or by the strong nucleophiles thiosulfate (TS) and diethyldithiocarbamate (DDTC). However, the Ptmethionine-like bond in Pt(dien)SMeG could be reversed by WR1065, although the reversal was slow (k2=0.142 m-1 s-1) as compared with that obtained using the modulating agents TS (k2=10.1 m-1 s-1) and DDTC (k2=3.66 m-1 s-1). WR2721 was hardly able to reverse the Pt-S bond in Pt(dien)SMeG (k2=0.00529 m-1 s-1), and WR33278 showed no capacity to do so. The activity of cis-diamminedichloroplatinum(II) (CDDP)-inactivated fumarase was not appreciably restored by any of the WR compounds (16%, 7.7%, and 0 for 20 mm WR1065, WR2721, and WR33278, respectively) in contrast to the strong nucleophile DDTC (61% for 2 mm DDTC). These in vitro studies provide information at the molecular level that may explain why WR2721, in contrast to DDTC, does not provide protection against cisplatin-induced nephrotoxicity when it is given after platinum-containing chemotherapy. The results support the present clinical use of WR2721 prior to the administration of platinum compounds.

Original languageEnglish (US)
Pages (from-to)467-470
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume29
Issue number6
DOIs
StatePublished - Nov 1992
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278'. Together they form a unique fingerprint.

Cite this